Torrent Pharmaceuticals Limited has informed the Exchange about Agreements
TORNTPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Torrent Pharma has agreed to buy a 46.39% controlling stake in J.B. Chemicals & Pharmaceuticals (JB Pharma) from KKR-promoted Tau Investment Holdings for about ₹11,917 crore at ₹1,600 per share. It will also launch a mandatory open offer for up to 26% of JB Pharma at ₹1,639.18 per share, and may buy another 2.80% from JB Pharma employees. After the open offer, the two companies will merge, with JB Pharma shareholders getting 51 Torrent shares for every 100 JB Pharma shares. The total equity valuation of JB Pharma is about ₹25,689 crore, and JB Pharma reported consolidated FY25 revenue of ₹3,918 crore against Torrent's ₹11,516 crore. The deal needs CCI, SEBI, NCLT and shareholder approvals and is expected to close within 6 months.
This is a large, debt-funded acquisition that makes JB Pharma a subsidiary and eventually merges it with Torrent, boosting combined scale and market share in India's pharma space. Short-term, Torrent's stock may see pressure over funding and integration risk; long-term, the deal aims to strengthen its chronic therapy portfolio and international footprint.